Chitosan-derivative compounds and methods of controlling microbial populations

• US 8,658,775 B2
• Filed: 12/13/2011
• Issued: 02/25/2014
• Est. Priority Date: 06/02/2006
• Status: Active Grant

• Current Assignee: Synedgen, Inc.
• Original Assignee: Synedgen, Inc.
• Inventors: Baker, Shenda, Wiesmann, William P., Ryan, Shannon
• Primary Examiner(s): BLAND, LAYLA D
• Application Number:
  US13/324,461
• Publication Number:
  US 20120329753A1
• Time in Patent Office: 805 Days
• Field of Search: None
• US Class Current: 536/20
• CPC Class Codes: A61K 31/722 Chitin, chitosan
• CPC Class Codes: A61K 8/736 Chitin; Chitosan; Derivatives thereof
• CPC Class Codes: A61L 2/232 layered or coated
• CPC Class Codes: A61L 2/235 cellular, porous or foamed
• CPC Class Codes: A61L 2202/23 Containers, e.g. vials, bottles, syringes, mail
• CPC Class Codes: A61L 2202/24 Medical instruments, e.g. endoscopes, catheters, sharps
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61Q 11/00 Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
• CPC Class Codes: A61Q 17/005 Antimicrobial preparations
• CPC Class Codes: C08B 37/003 Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.

Claims

1. A purified preparation comprising functionalized chitosan-derivatives, wherein said chitosan-derivatives comprise a plurality of poly lysine moieties covalently attached to a plurality of glucosamine primary amines of the chitosan.

2. The preparation as recited in claim 1, wherein the pH is between 6.8 and 7.4.

3. The preparation as recited in claim 2, wherein the functionalized chitosan-derivatives have a molecular weight in the range of 25,000 to 1,000,000 Da.

4. The preparation as recited in claim 3, wherein said molecular weight is in the range of 25,000 to 350,000 Da.

5. The preparation as recited in claim 3, wherein the degree of functionalization of the chitosan-derivative comprises between 7% and 30% poly lysine.

6. The preparation as recited in claim 5, further comprising salts of said functionalized chitosan-derivatives.